Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Antibody Structure

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High glucose-primed HUVEC-derived extracellular vesicles encapsulated in microgels boost diabetic ischaemic flap regeneration via HIF-1α/VEGF pathway.

Journal of nanobiotechnology·2026

Same author

Preclinical evaluation of an mRNA vaccine developed from the first human isolate of bovine H5N1.

Cell reports. Medicine·2026

Same author

Melanoma-secreted melanosome-MHC I disrupts T cell antitumor immunity.

Trends in cancer·2026

Same author

Lipid-induced granules in hepatocytes alleviate liver fibrosis.

Cell metabolism·2026

Same author

Functional and Metabolic Heterogeneity of Dendritic Cells in Self-Tolerance and Autoimmunity.

Immunological reviews·2025

Same author

Effectiveness of Anti-CD20 B cells depleting therapy versus conventional treatment in severe Anti-N-methyl-d-aspartate receptor encephalitis: A real-world multi-center prospective cohort study.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025

Search research articles

Related Experiment Video

Updated: Sep 5, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Antibody variable region engineering for improving cancer immunotherapy.

Hantao Lou^1,2, Xuetao Cao^2,3

¹Ludwig Institute of Cancer Research, University of Oxford, Oxford, OX3 7DR, UK.

Cancer Communications (London, England)

|July 13, 2022

Summary

Novel antibody fragments engineered for cancer immunotherapy enhance targeting of tumor and killer cells. This review explores antibody variable region engineering for improved cancer therapy potency, efficacy, and specificity.

Keywords:

antibody engineering bi/trispecific killer engager cancer immunotherapy chimeric antigen receptor-T (CAR-T) cell nanobody natural killer (NK) cell scFv

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Experiment Videos

Last Updated: Sep 5, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Area of Science:

Oncology
Immunology
Biotechnology

Background:

Conventional monoclonal antibody (mAb) drugs show limitations in clinical efficacy and specificity.
Cancer immunotherapy is a rapidly evolving field with a need for more effective treatments.

Purpose of the Study:

To review advancements in antibody variable region engineering for cancer immunotherapy.
To discuss future directions in antibody engineering to enhance cancer therapies.

Main Methods:

Engineering of variable region-retaining antibody fragments like antigen-binding fragment (Fab) and single-chain variable fragment (scFv).
Development of bispecific antibodies and bi/trispecific cell engagers.
Application of techniques including humanization, multivalent construction, affinity optimization, and antibody masking.

Main Results:

Engineered antibody formats demonstrate improved targeting of tumor cells and immune effector cells.
These novel formats aim to increase the potency, efficacy, and specificity of antibody-based cancer therapies.

Conclusions:

Antibody variable region engineering offers promising strategies to overcome limitations of conventional mAbs.
Future research in antibody engineering holds significant potential for advancing cancer immunotherapy.